Chinese General Practice ›› 2022, Vol. 25 ›› Issue (32): 4046-4051.DOI: 10.12114/j.issn.1007-9572.2022.0633
• Article • Previous Articles Next Articles
Received:
2022-05-20
Revised:
2022-08-15
Published:
2022-11-15
Online:
2022-09-01
Contact:
LIU Hengwei
About author:
通讯作者:
刘恒炜
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0633
指标 | PCOS |
---|---|
年龄(岁) | 27(24,29) |
BMI(kg/m2) | 25.5(22.9,28.3) |
T(nmol/L) | 1.48(1.05,1.94) |
DHEA(nmol/L) | 24.49(15.79,36.36) |
A(nmol/L) | 8.95(6.77,11.08) |
FT(pmol/L) | 8.40(6.44,10.88) |
SHBG(nmol/L) | 36.36(24.20,63.25) |
FAI | 3.65(1.87,6.76) |
HbA1c(%) | 3.91(2.56,6.08) |
HOMA-IR | 5.30(5.00,5.50) |
Table 1 Clinical and endocrine characteristics of PCOS patients
指标 | PCOS |
---|---|
年龄(岁) | 27(24,29) |
BMI(kg/m2) | 25.5(22.9,28.3) |
T(nmol/L) | 1.48(1.05,1.94) |
DHEA(nmol/L) | 24.49(15.79,36.36) |
A(nmol/L) | 8.95(6.77,11.08) |
FT(pmol/L) | 8.40(6.44,10.88) |
SHBG(nmol/L) | 36.36(24.20,63.25) |
FAI | 3.65(1.87,6.76) |
HbA1c(%) | 3.91(2.56,6.08) |
HOMA-IR | 5.30(5.00,5.50) |
组别 | 例数 | BMI(kg/m2) | T(nmol/L) | DHEA(nmol/L) |
---|---|---|---|---|
NGT组 | 490 | 24.04(21.90,26.70) | 1.49(1.07,1.92) | 24.47(15.37,35.74) |
IGT组 | 369 | 26.69(24.29,29.27)a | 1.49(1.05,2.00) | 24.70(15.97,36.94) |
T2DM组 | 95 | 28.40(26.32,31.60)ab | 1.43(0.89,1.97) | 23.60(15.41,35.29) |
H值 | 139.29 | 0.93 | 0.37 | |
P值 | <0.001 | 0.627 | 0.832 | |
组别 | A(nmol/L) | FT(pmol/L) | SHBG(nmol/L) | FAI |
NGT组 | 8.92(6.69,11.12) | 7.96(6.22,10.19) | 44.61(28.73,73.64) | 2.99(1.67,5.39) |
IGT组 | 9.08(6.93,11.05) | 8.72(6.71,11.33)a | 32.02(21.66,54.36)a | 4.52(2.16,7.46)a |
T2DM组 | 8.67(6.80,11.24) | 9.66(7.53,12.93)a | 23.11(15.66,31.51)ab | 6.48(2.63,9.18)ab |
H值 | 0.32 | 24.35 | 79.95 | 42.93 |
P值 | 0.854 | <0.001 | <0.001 | <0.001 |
Table 2 Comparison of BMI and androgen levels in PCOS patients with different glucose tolerance
组别 | 例数 | BMI(kg/m2) | T(nmol/L) | DHEA(nmol/L) |
---|---|---|---|---|
NGT组 | 490 | 24.04(21.90,26.70) | 1.49(1.07,1.92) | 24.47(15.37,35.74) |
IGT组 | 369 | 26.69(24.29,29.27)a | 1.49(1.05,2.00) | 24.70(15.97,36.94) |
T2DM组 | 95 | 28.40(26.32,31.60)ab | 1.43(0.89,1.97) | 23.60(15.41,35.29) |
H值 | 139.29 | 0.93 | 0.37 | |
P值 | <0.001 | 0.627 | 0.832 | |
组别 | A(nmol/L) | FT(pmol/L) | SHBG(nmol/L) | FAI |
NGT组 | 8.92(6.69,11.12) | 7.96(6.22,10.19) | 44.61(28.73,73.64) | 2.99(1.67,5.39) |
IGT组 | 9.08(6.93,11.05) | 8.72(6.71,11.33)a | 32.02(21.66,54.36)a | 4.52(2.16,7.46)a |
T2DM组 | 8.67(6.80,11.24) | 9.66(7.53,12.93)a | 23.11(15.66,31.51)ab | 6.48(2.63,9.18)ab |
H值 | 0.32 | 24.35 | 79.95 | 42.93 |
P值 | 0.854 | <0.001 | <0.001 | <0.001 |
变量 | Glu 0 min(mmol/L) | Glu 30 min(mmol/L) | Glu 60 min(mmol/L) | Glu 120 min(mmol/L) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | |
T | 0.005 | (-0.058,0.069) | 0.866 | 0.068 | (0.004,0.131) | 0.037 | 0.042 | (-0.022,0.105) | 0.199 | 0.019 | (-0.044,0.083) | 0.549 |
DHEA | 0.031 | (-0.033,0.094) | 0.346 | 0.054 | (-0.009,0.118) | 0.093 | 0.055 | (-0.008,0.119) | 0.088 | 0.025 | (-0.039,0.088) | 0.446 |
A | 0.039 | (-0.024,0.103) | 0.225 | 0.010 | (-0.053,0.074) | 0.750 | 0.046 | (-0.017,0.110) | 0.155 | 0.018 | (-0.045,0.082) | 0.572 |
FT | 0.055 | (-0.008,0.119) | 0.088 | 0.057 | (-0.006,0.121) | 0.078 | 0.051 | (-0.012,0.115) | 0.112 | 0.034 | (-0.029,0.098) | 0.290 |
SHBG | -0.160 | (-0.223,-0.098) | <0.001 | -0.154 | (-0.217,-0.091) | <0.001 | -0.200 | (-0.262,-0.137) | <0.001 | -0.188 | (-0.251,-0.126) | <0.001 |
FAI | 0.210 | (0.148,0.273) | <0.001 | 0.268 | (0.207,0.329) | <0.001 | 0.291 | (0.230,0.352) | <0.001 | 0.275 | (0.214,0.336) | <0.001 |
变量 | Glu 180 min(mmol/L) | HbA1c(%) | 胰岛素 | HOMA-IR | ||||||||
β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | |
T | 0.018 | (-0.045,0.082) | 0.574 | 0.032 | (-0.032,0.095) | 0.330 | 0.098 | (0.035,0.161) | 0.002 | 0.086 | (0.022,0.149) | 0.008 |
DHEA | 0.017 | (-0.047,0.080) | 0.610 | -0.025 | (-0.089,0.038) | 0.435 | -0.01 | (-0.074,0.054) | 0.760 | 0 | (-0.064,0.063) | 0.989 |
A | 0.032 | (-0.032,0.096) | 0.323 | 0.013 | (-0.051,0.076) | 0.691 | 0.034 | (-0.029,0.098) | 0.288 | 0.032 | (-0.032,0.095) | 0.327 |
FT | -0.003 | (-0.067,0.060) | 0.924 | 0.055 | (-0.008,0.119) | 0.089 | 0.057 | (-0.007,0.120) | 0.080 | 0.060 | (-0.004,0.123) | 0.065 |
SHBG | -0.096 | (-0.159,-0.033) | 0.003 | -0.187 | (-0.249,-0.124) | <0.001 | -0.226 | (-0.288,-0.164) | <0.001 | -0.224 | (-0.286,-0.162) | <0.001 |
FAI | 0.157 | (0.094,0.219) | <0.001 | 0.277 | (0.216,0.338) | <0.001 | 0.371 | (0.312,0.430) | <0.001 | 0.377 | (0.318,0.436) | <0.001 |
Table 3 Multiple linear regression to evaluate the effects of androgen indexeson glucose metabolism in women with PCOS
变量 | Glu 0 min(mmol/L) | Glu 30 min(mmol/L) | Glu 60 min(mmol/L) | Glu 120 min(mmol/L) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | |
T | 0.005 | (-0.058,0.069) | 0.866 | 0.068 | (0.004,0.131) | 0.037 | 0.042 | (-0.022,0.105) | 0.199 | 0.019 | (-0.044,0.083) | 0.549 |
DHEA | 0.031 | (-0.033,0.094) | 0.346 | 0.054 | (-0.009,0.118) | 0.093 | 0.055 | (-0.008,0.119) | 0.088 | 0.025 | (-0.039,0.088) | 0.446 |
A | 0.039 | (-0.024,0.103) | 0.225 | 0.010 | (-0.053,0.074) | 0.750 | 0.046 | (-0.017,0.110) | 0.155 | 0.018 | (-0.045,0.082) | 0.572 |
FT | 0.055 | (-0.008,0.119) | 0.088 | 0.057 | (-0.006,0.121) | 0.078 | 0.051 | (-0.012,0.115) | 0.112 | 0.034 | (-0.029,0.098) | 0.290 |
SHBG | -0.160 | (-0.223,-0.098) | <0.001 | -0.154 | (-0.217,-0.091) | <0.001 | -0.200 | (-0.262,-0.137) | <0.001 | -0.188 | (-0.251,-0.126) | <0.001 |
FAI | 0.210 | (0.148,0.273) | <0.001 | 0.268 | (0.207,0.329) | <0.001 | 0.291 | (0.230,0.352) | <0.001 | 0.275 | (0.214,0.336) | <0.001 |
变量 | Glu 180 min(mmol/L) | HbA1c(%) | 胰岛素 | HOMA-IR | ||||||||
β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | |
T | 0.018 | (-0.045,0.082) | 0.574 | 0.032 | (-0.032,0.095) | 0.330 | 0.098 | (0.035,0.161) | 0.002 | 0.086 | (0.022,0.149) | 0.008 |
DHEA | 0.017 | (-0.047,0.080) | 0.610 | -0.025 | (-0.089,0.038) | 0.435 | -0.01 | (-0.074,0.054) | 0.760 | 0 | (-0.064,0.063) | 0.989 |
A | 0.032 | (-0.032,0.096) | 0.323 | 0.013 | (-0.051,0.076) | 0.691 | 0.034 | (-0.029,0.098) | 0.288 | 0.032 | (-0.032,0.095) | 0.327 |
FT | -0.003 | (-0.067,0.060) | 0.924 | 0.055 | (-0.008,0.119) | 0.089 | 0.057 | (-0.007,0.120) | 0.080 | 0.060 | (-0.004,0.123) | 0.065 |
SHBG | -0.096 | (-0.159,-0.033) | 0.003 | -0.187 | (-0.249,-0.124) | <0.001 | -0.226 | (-0.288,-0.164) | <0.001 | -0.224 | (-0.286,-0.162) | <0.001 |
FAI | 0.157 | (0.094,0.219) | <0.001 | 0.277 | (0.216,0.338) | <0.001 | 0.371 | (0.312,0.430) | <0.001 | 0.377 | (0.318,0.436) | <0.001 |
组别 | 例数 | Ins 0 min(μU/ml) | Ins 30 min(μU/ml) | Ins 60 min(μU/ml) | Ins 120 min(μU/ml) | Ins 180 min(μU/ml) | HOMA-IR |
---|---|---|---|---|---|---|---|
Q1亚组 | 238 | 12.88 (8.58,19.16) | 101.68(69.56,148.93) | 117.67(80.72,174.64) | 92.88(54.91,147.94) | 32.02(16.56,69.35) | 5.10 (4.90,5.40) |
Q2亚组 | 238 | 13.73(9.41,20.39) | 102.32(66.72,160.21) | 123.90(79.04,191.30) | 93.33(56.93,147.53) | 33.41(19.76,59.73) | 5.20(5.00,5.50) |
Q3亚组 | 239 | 17.26(12.17,24.45)ab | 120.03(82.83,173.51)ab | 142.54(98.96,205.53)ab | 116.93(73.27,175.46)ab | 44.54(22.15,74.27) | 5.20(5.00,5.50)ab |
Q4亚组 | 239 | 23.24(15.38,32.15)abc | 129.84(87.41,192.94)abc | 173.27(120.76,255.63)abc | 158.19(105.66,248.72)abc | 61.68(34.36,105.03)abc | 5.40(5.10,5.70)abc |
H值 | 115.64 | 30.32 | 59.12 | 89.45 | 67.40 | 125.06 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 4 Changes of insulin levels in PCOS patients with different FAI subgroups
组别 | 例数 | Ins 0 min(μU/ml) | Ins 30 min(μU/ml) | Ins 60 min(μU/ml) | Ins 120 min(μU/ml) | Ins 180 min(μU/ml) | HOMA-IR |
---|---|---|---|---|---|---|---|
Q1亚组 | 238 | 12.88 (8.58,19.16) | 101.68(69.56,148.93) | 117.67(80.72,174.64) | 92.88(54.91,147.94) | 32.02(16.56,69.35) | 5.10 (4.90,5.40) |
Q2亚组 | 238 | 13.73(9.41,20.39) | 102.32(66.72,160.21) | 123.90(79.04,191.30) | 93.33(56.93,147.53) | 33.41(19.76,59.73) | 5.20(5.00,5.50) |
Q3亚组 | 239 | 17.26(12.17,24.45)ab | 120.03(82.83,173.51)ab | 142.54(98.96,205.53)ab | 116.93(73.27,175.46)ab | 44.54(22.15,74.27) | 5.20(5.00,5.50)ab |
Q4亚组 | 239 | 23.24(15.38,32.15)abc | 129.84(87.41,192.94)abc | 173.27(120.76,255.63)abc | 158.19(105.66,248.72)abc | 61.68(34.36,105.03)abc | 5.40(5.10,5.70)abc |
H值 | 115.64 | 30.32 | 59.12 | 89.45 | 67.40 | 125.06 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
指标 | HOMA-IR | HOMA-IR'(调整BMI后) | ||
---|---|---|---|---|
rs值 | P值 | R值 | P'值 | |
T | 0.069 | 0.034 | 0.095 | 0.003 |
DHEA | -0.013 | 0.697 | 0.014 | 0.676 |
A | 0.057 | 0.078 | 0.070 | 0.031 |
FT | 0.263 | <0.001 | 0.036 | 0.267 |
SHBG | -0.438 | <0.001 | -0.138 | <0.001 |
FAI | 0.363 | <0.001 | 0.288 | <0.001 |
Table 5 The correlation between HOMA-IR and androgen indexes
指标 | HOMA-IR | HOMA-IR'(调整BMI后) | ||
---|---|---|---|---|
rs值 | P值 | R值 | P'值 | |
T | 0.069 | 0.034 | 0.095 | 0.003 |
DHEA | -0.013 | 0.697 | 0.014 | 0.676 |
A | 0.057 | 0.078 | 0.070 | 0.031 |
FT | 0.263 | <0.001 | 0.036 | 0.267 |
SHBG | -0.438 | <0.001 | -0.138 | <0.001 |
FAI | 0.363 | <0.001 | 0.288 | <0.001 |
变量 | 正常体质量 | 超重 | 肥胖 | ||||||
---|---|---|---|---|---|---|---|---|---|
β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | |
T | -0.034 | (-0.143,0.075) | 0.540 | 0.077 | (-0.027,0.180) | 0.147 | 0.154 | (0.035,0.274) | 0.012 |
DHEA | -0.037 | (-0.146,0.072) | 0.501 | 0.021 | (-0.083,0.125) | 0.688 | 0.024 | (-0.097,0.145) | 0.698 |
A | 0.033 | (-0.076,0.142) | 0.548 | 0.054 | (-0.050,0.157) | 0.312 | 0.132 | (0.012,0.252) | 0.031 |
FT | 0.119 | (0.011,0.227) | 0.031 | 0.009 | (-0.095,0.113) | 0.860 | 0.291 | (0.175,0.407) | <0.001 |
SHBG | -0.155 | (-0.262,-0.048) | 0.005 | -0.199 | (-0.301,-0.097) | <0.001 | -0.176 | (-0.295,-0.057) | 0.004 |
FAI | 0.083 | (-0.025,0.192) | 0.131 | 0.249 | (0.148,0.350) | <0.001 | 0.390 | (0.278,0.501) | <0.001 |
Table 6 Effect of androgen on HOMA-IR in PCOS patients with different body weights
变量 | 正常体质量 | 超重 | 肥胖 | ||||||
---|---|---|---|---|---|---|---|---|---|
β | 95%CI | P值 | β | 95%CI | P值 | β | 95%CI | P值 | |
T | -0.034 | (-0.143,0.075) | 0.540 | 0.077 | (-0.027,0.180) | 0.147 | 0.154 | (0.035,0.274) | 0.012 |
DHEA | -0.037 | (-0.146,0.072) | 0.501 | 0.021 | (-0.083,0.125) | 0.688 | 0.024 | (-0.097,0.145) | 0.698 |
A | 0.033 | (-0.076,0.142) | 0.548 | 0.054 | (-0.050,0.157) | 0.312 | 0.132 | (0.012,0.252) | 0.031 |
FT | 0.119 | (0.011,0.227) | 0.031 | 0.009 | (-0.095,0.113) | 0.860 | 0.291 | (0.175,0.407) | <0.001 |
SHBG | -0.155 | (-0.262,-0.048) | 0.005 | -0.199 | (-0.301,-0.097) | <0.001 | -0.176 | (-0.295,-0.057) | 0.004 |
FAI | 0.083 | (-0.025,0.192) | 0.131 | 0.249 | (0.148,0.350) | <0.001 | 0.390 | (0.278,0.501) | <0.001 |
[1] |
|
[2] | |
[3] |
|
[4] |
Rotterdam Eshre/Asrm-Sponsored Pcos Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril,2004,81(1):19-25. DOI:10.1016/j.fertnstert.2003.10.004.
|
[5] |
|
[6] |
|
[7] |
中华医学会糖尿病学分会胰岛素抵抗学组. 胰岛素抵抗评估方法和应用的专家指导意见[J]. 中华糖尿病杂志,2018,10(6):377-385. DOI:10.3760/cma.j.issn.1674-5809.2018.06.001.
|
[8] |
中国肥胖问题工作组. 中国成人超重和肥胖症预防与控制指南(节录)[J]. 营养学报,2004(1):1-4.
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[1] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[2] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[3] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[4] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[5] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[6] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[7] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[8] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[9] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[10] | GAO Dekang, WEI Shaohua, MA Xiaoming, DU Peng, XING Chungen, CAO Chun. Risk Factors for Loss of Skeletal Muscle Mass and Its Correlation with Complications after Major Hepatectomy for Liver Cancer [J]. Chinese General Practice, 2023, 26(32): 4031-4037. |
[11] | ZHANG Juan, LI Haifen, LI Xiaoman, YAO Miao, MA Huizhen, MA Qiang. Construction of Recurrence Risk Prediction Model for Diabetic Foot Ulcer on the Basis of Logistic Regression, Support Vector Machine and BP Neural Network Model [J]. Chinese General Practice, 2023, 26(32): 4013-4019. |
[12] | GAO Jing, ZHOU Shangcheng, GAO Sande, ZOU Guanyang, CHEN Yingyao. Health-related Quality of Life and Its Influencing Factors in Patients with Prevention of Disease in Traditionnal Chinese Medicine based on EQ-5D-5L Scale [J]. Chinese General Practice, 2023, 26(32): 4043-4050. |
[13] | WANG Minghuan, LI Yuhong, YU Min, WANG Yougang, YU Qiaozhi, YANG Fangfang, YUAN Dehui, ZHANG Liu. Effect of Allostatic Load on Adverse Pregnancy Outcomes of Women in Late Pregnancy [J]. Chinese General Practice, 2023, 26(32): 4064-4069. |
[14] | YUAN Dehui, LI Yuhong, XIONG Min, YU Min, MA Ruiliang, YANG Fangfang, YU Qiaozhi, WANG Minghuan. Status and Influencing Factors of Allostatic Load in Pregnant Women at Different Trimesters [J]. Chinese General Practice, 2023, 26(32): 4057-4063. |
[15] | DUAN Yanqin, PENG Ying, LIU Shenglan, LIU Haijiao, YANG Huiqiong, HU Haiqing. Prevalence and Associated Factors of Potentially Inappropriate Medication among Elderly Outpatients [J]. Chinese General Practice, 2023, 26(31): 3902-3907. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||